Antimicrobial susceptibility testing 120
Susceptibility of isolates (minimum inhibitory concentrations [MICs] ) to metronidazole, 121 vancomycin, rifampicin, chloramphenicol (Sigma), moxifloxacin (Bayer), clindamycin, 122 tigecycline (Pfizer), imipenem (MSD) and fidaxomicin (Astellas) were determined using a 123
Clinical and Laboratory Standards Institute agar incorporation method with Wilkins-Chalgren 124
agar [6, 8, 9] and breakpoints, as previously described [6] . 125
126

Cumulative resistance scores 127
MIC results for each isolate were designated susceptible (S), intermediately resistant (I) or 128 fully resistant (R), according to breakpoints, and assigned a score (S=0, I=1 and R=2). A 129 cumulative resistance score (CRS) based on susceptibility to each of the nine antimicrobials 130 tested was then generated for each isolate. Thus, an isolate that was fully susceptible to 131 four, intermediately resistant to two, and resistant to three antimicrobials would generate a 132 CRS of 8 (0 + 0 + 0 + 0 + 1 + 1 + 2 + 2 + 2). Isolates were grouped by country, and mean 133
CRSs were generated for each country over the three years. 134
Results
136
Over three years, 2830 samples/isolates (from 39 sites in 22 countries) were submitted to 137 the central laboratory for testing, yielding 2694 C. difficile isolates (95.3%). Of these, 95.6% 138 (n=2577) were toxin-positive. 139
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7
In Year 1, 114 known PCR RTs were isolated from samples; in Year 2, 144; and in Year 3, 142 120. The most commonly isolated European RT was RT027, which accounted for: 12.2% 143 (n=115/943) in Year 1; 11.8% (n=112/948) in Year 2; and 12.6% (n=101/804) in Year 3. The 144 prevalence of other RTs is presented in Table 1 . 145
RT prevalence differed by region, with certain countries exhibiting highly predominant RTs, 146 and others showing a diverse range of RTs (Fig. 1a-c Fig. 1a-c) . 151
RT diversity scores were calculated for each country (total number of RTs detected in that 152 country divided by the number of isolates tested from that country). Scores closest to 1 and 153 0 indicated the greatest and least diversity of RTs, respectively. Belgium submitted the 154 greatest diversity of RTs in Years 1 and 2, with scores of 0.96 and 0.80, respectively. 155
156
Antimicrobial susceptibility 157
All isolates were susceptible to fidaxomicin, with geometric mean MICs of 0.04-0.05 mg/L 158 (Table 2a) , and a normal unimodal distribution for all study years (Fig. 2) . Among prevalent 159
RTs, only RT027 and RT198 showed evidence of increased geometric mean MICs: in Years 160 1-3, from 0.04 to 0.08 mg/L for RT027; and from 0.04 to 0.10 mg/L for RT198 (Table 3) . 161
Metronidazole, vancomycin and tigecycline were active against 97.9% (n=2692/2698), 162 98.6% (n=2659/2698) and 100.0%, respectively, of isolates tested. There was little variation 163 in sensitive, intermediate and resistant isolates collected across Europe during Years 1-3M A N U S C R I P T
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Higher geometric mean vancomycin MICs were observed for RT018 (2.00 mg/L) and RT356 167 (2.28 mg/L, Year 1 only) (Table 3) . No particular RTs were associated with vancomycin 168
resistance. 169
The proportion of isolates showing rifampicin resistance was similar in Years 1 and 2, with a 170 slight reduction in Year 3 (Table 2b) (Table 3) . 178
Moxifloxacin and clindamycin resistance was widespread, particularly among some of the 179 more prevalent RTs (Table 3 ). Moxifloxacin resistance decreased over Years 1-3 from 180 39.5% (n=372/943) to 33.5% (n=269/803). Clindamycin resistance increased from 49.8% 181 (n=470/943) to 64.3% (n=516/803) (Table 2b ), but showed variations in the proportion of 182 resistant isolates from the same country, possibly due to fluctuations in individual RT 183
prevalence. 184
The majority of isolates were sensitive to imipenem (Table 2b ). Geometric mean MICs were 185 marginally higher for RT027 and RT198 than for most other RTs during the study period 186 (Table 3) . During Years 2 and 3, there was evidence of decreasing imipenem susceptibility 187 to RT017 (geometric mean MIC: 9.8 mg/L and 10.6 mg/L, respectively) ( Table 3) . Most 188 isolates were susceptible to chloramphenicol (Table 2b) (Table 3) . prospective, biannual, point-prevalence study of CDI in hospitalised patients with diarrhoea), 220 in which the incidence of RT027 was 19% among 1196 C. difficile isolates tested [4], our 221 study found a lower incidence (11.8-12.6%) for this RT. This variability may result from the 222 greater number of isolates tested in our study, leading to different levels of prevalence for 223 each RT. Our study also demonstrated that RTs reported previously as highly prevalent 224 (RT001 in Latvia and Slovakia, RT027 in Poland and Hungary, and RT017 and RT176 in the 225
Czech Republic) remained so in those countries. 226
The emergence of RT356 in Italy in Year 1, with its accompanying high levels of 227 antimicrobial resistance, has been described [6,13] (24 th European Congress of Clinical 228
Microbiology and Infectious Diseases [ECCMID], abstract R483). PCR banding profiles of 229
RT018 and RT356 are closely related (94% similarity) and genome sequencing of these 230 isolates may inform both strain provenance and resistance development [6] . As reported 231 
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It has been suggested that so-called 'hypervirulent' C. difficile strains (including RT027) may 242 be less susceptible to fidaxomicin than other RTs [14] . Only small differences in fidaxomicin 243 susceptibility were observed between RTs in our study. Notably, the increase in geometric 244 mean fidaxomicin MICs for RT027 was merely 0.04 mg/L over three years. The significance 245 of this observation is questionable, particularly in the context of high faecal fidaxomicin 246 concentrations during therapy (>1000 g/g), which are >5000-fold higher than the MIC 90 247
[16]. 248
Reduced metronidazole susceptibility was uncommon across all years, and most evident 249 among RT027 and RT198, as previously described [ 
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